Endotronix presented positive six-month results from its PROACTIVE-HF pivotal trial of the investigational Cordella Pulmonary Artery (PA) Sensor on March 5. The trial, in New York Heart Association ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted premarket approval to Endotronix’s pulmonary artery sensor platform for remote management of ...
Please provide your email address to receive an email when new articles are posted on . Abbott announced its sensor providing hemodynamic-guided management of patients with HF has received an expanded ...
Endotronix Inc. reported positive data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella pulmonary artery pressure sensor system in New York Heart Association (NYHA) ...
It’s been part of Bill Keiss daily routine for nearly a year. “I get up in the morning and I take all my vitals,” Keiss, 71, said. Stream NBC 5 for free, 24/7, wherever you are. Suffering from ...
For most patients suffering from heart failure today, care is episodic. Medication and other treatments are only adjusted when a patient is hospitalized or sees their doctor during periodic office ...
Endotronix has secured an FDA approval for its early warning sensor implant to remotely track patients with serious and potentially worsening heart failure. The minimally invasive Cordella system ...
TEL AVIV, Israel--(BUSINESS WIRE)--Vectorious Medical Technologies Ltd., today announced that it has enrolled the first six patients in the VECTOR-HF II Study, which will evaluate the V-LAP System’s ...
There is a critical need for non-invasive solutions to monitor heart failure progression around the clock. This novel wearable device is based on sensors embedded in a lightweight belt that monitors ...
A small, inexpensive sensor may be able to help people with heart failure monitor their condition without visiting a hospital. Trey Pittman, a graduate student in Chuck Henry’s lab at Colorado State ...
The trial met primary safety and efficacy endpoints, demonstrating a markedly low rate of heart failure hospitalizations for NYHA class III HF patients. The results support the company's pre-market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback